高脱位发育性髋关节发育不良全髋关节置换术后阿司匹林预防静脉血栓栓塞风险高:一项回顾性比较研究
该回顾性比较研究纳入134例初次全髋关节置换术患者,比较Crowe III或IV型高脱位发育性髋关节发育不良(DDH)与其他诊断患者在接受阿司匹林预防后症状性静脉血栓栓塞(VTE)的发生率。高脱位DDH组症状性VTE发生率为17%(8/47),对照组为1%(1/87),校正后OR为67(95%CI 3至151;p=0.008)。高脱位DDH组中,肢体延长是唯一与症状性VTE风险增加相关的因素。
要点
- 高脱位DDH患者全髋置换术后阿司匹林预防下症状性VTE发生率为17%(8/47),对照组为1%(1/87)。
- 高脱位DDH组症状性VTE的校正OR为67(95%CI 3至151;p=0.008)。
- 高脱位DDH组中肢体延长是症状性VTE唯一相关因素,中位延长38 mm vs 25 mm(p=0.002)。
核心结论
- 高脱位DDH患者接受全髋关节置换术并以阿司匹林预防VTE时,症状性VTE(包括深静脉血栓和肺栓塞)的可能性高于其他指征的初次全髋关节置换术患者。
- 在该组患者中,术中肢体延长程度更大似乎进一步增加VTE风险。
- 作者建议,在更大规模的多变量研究明确该问题之前,对于高脱位DDH行全髋关节置换术的患者,医生应考虑使用比阿司匹林更强效的血栓预防药物,并在术后特别警惕VTE的症状和体征。
研究设计与样本
- 回顾性比较研究,纳入2021年6月至11月期间在两个关节置换中心由一位关节置换外科医生连续实施的153例初次全髋关节置换术(146例患者)。
- 排除有VTE病史(1% [2/146])、持续抗凝治疗(2% [3/146])、超出年龄标准范围(2% [3/146])、同期双侧或分期双侧第二侧全髋置换(3% [4/146])及术后90天内失访(0% [0/146])者后,最终分析134例患者(134髋)。
- 按术前诊断分为高脱位DDH(Crowe III或IV型)组35%(47/134髋)和其他诊断对照组65%(87/134髋)。
- 所有患者除有既往VTE史或长期抗凝者外均接受阿司匹林作为药物预防,未进行常规VTE监测。
- 证据等级为III级,治疗性研究。
主要发现
- 高脱位DDH组症状性VTE发生率为17%(8/47),对照组为1%(1/87),OR 18(95%CI 2至146;p=0.001)。
- 校正年龄、性别、ASA分级、麻醉类型、手术时间、短缩截骨、植骨/打压植骨及输血等混杂因素后,高脱位DDH组症状性VTE的校正OR为67(95%CI 3至151;p=0.008)。
- 仅考虑近端深静脉血栓或肺栓塞(排除远端深静脉血栓)时,高脱位DDH组发生率为11%(5/47),对照组为1%(1/87),OR 10(95%CI 1至90;p=0.02)。
- 在高脱位DDH组中,控制潜在混杂变量后,肢体延长是唯一与症状性VTE可能性增加相关的因素,中位延长38 mm(范围25至60)vs 25 mm(范围15至50);p=0.002。
关键数值与推荐
- 高脱位DDH定义为Crowe III或IV型。
- 症状性VTE包括远端深静脉血栓、近端深静脉血栓或肺栓塞。
- 高脱位DDH组症状性VTE发生率17%(8/47),对照组1%(1/87)。
- 高脱位DDH组校正OR 67(95%CI 3至151;p=0.008)。
- 高脱位DDH组肢体延长中位38 mm(范围25至60)vs 对照组25 mm(范围15至50);p=0.002。
临床怎么用
- 作者建议,对于高脱位DDH行全髋关节置换术的患者,医生应考虑使用比阿司匹林更强效的血栓预防药物。
- 作者建议,在高脱位DDH行全髋关节置换术患者的术后期间特别警惕VTE的症状和体征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite advancements, THA is still associated with risks, particularly venous thromboembolism (VTE). THA in patients with high-riding developmental dysplasia of the hip (DDH) could potentially be associated with an elevated risk of VTE. We conducted a study to evaluate whether patients with high-riding DDH undergoing THA and receiving aspirin have an increased risk of symptomatic VTE compared with patients undergoing primary THA for other diagnoses. Additionally, we investigated possible risk factors for VTE within this specific patient group. QUESTIONS/PURPOSES: (1) Is the risk of symptomatic VTE (all deep vein thrombosis [DVT] plus pulmonary embolism, or proximal DVT plus pulmonary embolism) increased in patients undergoing THA for severe DDH, defined as Crowe type III or IV, compared with patients undergoing THA for other reasons when aspirin is used for prophylaxis? (2) In patients with severe DDH undergoing THA, are there specific identifiable risk factors associated with an increased risk of symptomatic VTE? METHODS: Between June and November 2021, an arthroplasty surgeon performed 153 consecutive primary THAs on 146 patients across two arthroplasty centers. All patients except those with a history of prior VTE or those on chronic anticoagulation received aspirin as pharmacologic prophylaxis for VTE. No routine surveillance for VTE was used. To be eligible for this retrospective comparative study, a chart note documenting any signs or symptoms of symptomatic VTE had to be present at least 3 months postoperatively. Patients were excluded for the following reasons: they had a personal history of VTE (1% [2 of 146]), they were receiving ongoing anticoagulant therapy (2% [3 of 146]), they were out of the age criteria range (2% [3 of 146]), they had undergone same-setting bilateral THAs or the second side of staged bilateral THAs (3% [4 of 146]), or they were lost to follow-up within 90 days after surgery (0% [0]). After exclusions, 134 patients (134 hips) remained. Patients were divided into two groups based on their preoperative diagnosis: (1) high-riding DDH of Crowe type III or IV (35% [47 of 134] of hips) and (2) all other diagnoses, including primary or inflammatory arthritis, Crowe type I or II DDH, fracture, and osteonecrosis (65% [87 of 134] of hips). A comprehensive records review was conducted to determine the incidence of symptomatic VTE, including distal DVT, proximal DVT, or pulmonary embolism. Patients' demographics, surgical details, and outcomes were compared between the groups. The high-riding group had longer operations and a higher percentage of patients having general anesthesia, acetabular bone grafting, transfusions, or restricted weightbearing postoperatively. Univariable analysis was performed to compare the high-riding DDH group with the control group and to evaluate associations between potential risk factors and symptomatic VTE. Subsequently, multivariable logistic regression was conducted to identify independent risk factors among the variables identified in the univariable analysis. RESULTS: Patients undergoing THA for DDH had higher odds of experiencing symptomatic VTE compared with the control group (17% [8 of 47] versus 1% [1 of 87], OR 18 [95% confidence interval (CI) 2 to 146]; p = 0.001). After adjusting for confounding variables such as age, sex, American Society of Anesthesiologists grading, anesthesia type, operation duration, shortening osteotomy, shelf/impaction grafting, and blood transfusion, patients undergoing THA for high-riding DDH still had higher adjusted odds of symptomatic VTE compared with the other group (adjusted OR 67 [95% CI 3 to 151]; p = 0.008). When considering only proximal DVT or pulmonary embolism events (excluding distal DVT), the odds of experiencing a VTE event remained higher in patients with high-riding DDH compared with the other group (11% [5 of 47] versus 1% [1 of 87], OR 10 [95% CI 1 to 90]; p = 0.02). In patients undergoing THA for high-riding DDH, after controlling for potential confounding variables, limb lengthening was identified as the only factor associated with an increased likelihood of symptomatic VTE (median [range] lengthening 38 mm [25 to 60] versus 25 mm [15 to 50]; p = 0.002). CONCLUSION: Our findings showed that patients undergoing THA for high-riding developmental DDH and receiving aspirin for VTE prophylaxis had a higher likelihood of experiencing symptomatic VTE, including DVT and pulmonary embolism, compared with patients undergoing primary THA for other indications. Additionally, greater intraoperative limb lengthening in this group appeared to further increase the risk of VTE. While DDH may be a risk factor for symptomatic VTE after THA, this association could also be attributed to the increased complexity of the procedure in hips with high-riding DDH. Until larger studies with multivariable analyses of potential risk factors are conducted to clarify this issue, we recommend that surgeons consider using thromboprophylaxis agents more potent than aspirin for patients undergoing THA for high-riding DDH and remain particularly vigilant in the postoperative period for signs and symptoms of VTE. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Gharanizadeh K, Ravanbod H, Poursalehian M, et al. High Risk of Venous Thromboembolism With Aspirin Prophylaxis After THA for High-riding Developmental Dysplasia of the Hip: A Retrospective, Comparative Study. Clin Orthop Relat Res. 2025. PMID: 40536765. doi:10.1097/CORR.0000000000003482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。